Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity
Hanne M. Boen, Martina Cherubin, Constantijn Franssen, Andreas B. Gevaert, Isabel Witvrouwen, Matthias Bosman, Pieter‐Jan Guns, Hein Heidbüchel, Bart Loeys, Maaike Alaerts, Emeline M. Van Craenenbroeck
Abstract
Close monitoring for cardiotoxicity during anthracycline chemotherapy is crucial for early diagnosis and therapy guidance. Currently, monitoring relies on cardiac imaging and serial measurement of cardiac biomarkers like cardiac troponin and natriuretic peptides. However, these conventional biomarkers are nonspecific indicators of cardiac damage. Exploring new, more specific biomarkers with a clear link to the underlying pathomechanism of cardiotoxicity holds promise for increased specificity and sensitivity in detecting early anthracycline-induced cardiotoxicity. miRNAs (microRNAs), small single-stranded, noncoding RNA sequences involved in epigenetic regulation, influence various physiological and pathological processes by targeting expression and translation. Emerging as new biomarker candidates, circulating miRNAs exhibit resistance to degradation and offer a direct pathomechanistic link. This review comprehensively outlines their potential as early biomarkers for cardiotoxicity and their pathomechanistic link.